证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-------------------------|---------------------------------------|--------------------------------------------------------|-------| | | | 特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | 动类别 | □现场参观 | | | | | 其他（电话） | | | | | | 东吴证券研究所朱国广、徐梓煜、乔波耀、李倩 | | | | Pinpoint 卢聪， TKAMC | 刘勍，东方证券资管江琦 | | | | | 国海资管吴正明，国泰基金黄卓，泓澄投资殷萌 | | | | | 竑观投资朱戈宇，华夏财富程海泳，嘉实基金程佳、孙晓晖 | | | | | 建信郑丁源，江海自营罗萍，金元证券黄斌， | | | | | 景泰 ...

浙江昂利康制药股份有限公司 2022 年第三季度报告 证券代码：002940 证券简称：昂利康 公告编号：2022-102 浙江昂利康制药股份有限公司 2022 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重 大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报 告中财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 1 浙江昂利康制药股份有限公司 2022 年第三季度报告 （二） 非经常性损益项目和金额 适用 □不适用 | | | | 单位：元 | | --- | --- | --- | --- | | 项目 | 本报告期金额 | 年初至报告期期末金额 | 说明 | | 非流动资产处置损益（包括已计提资产减值准 | -143,107.47 | -198,933.82 | | | 备的冲销部分） | | | | | ...

Financial Performance - The company's operating revenue for the first half of 2022 was ¥703,784,547.08, representing an increase of 11.05% compared to ¥633,728,939.83 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2022 was ¥79,104,500.66, a 20.62% increase from ¥65,580,207.38 in the previous year[26]. - The net cash flow from operating activities increased by 61.37% to ¥212,313,335.25, up from ¥131,571,852.44 in the same period last year[26]. - The total assets at the end of the reporting period were ¥2,356,716,745.93, reflecting a growth of 13.11% from ¥2,083,578,310.62 at the end of the previous year[26]. - The company’s basic earnings per share increased by 23.53% to ¥0.84, compared to ¥0.68 in the same period last year[26]. - The company's operating profit for the first half of 2022 was ¥93.83 million, up 6.66% from ¥87.88 million in the first half of 2021[190]. - The company achieved an investment income of ¥6.56 million, a recovery from a loss of ¥5.63 million in the first half of 2021[190]. - The tax expense for the first half of 2022 was ¥7.75 million, down 33.06% from ¥11.59 million in the previous year[190]. Research and Development - The company is focused on enhancing its research and development capabilities to drive innovation in its product offerings[5]. - Research and development expenses rose significantly by 73.14% to ¥39,657,679.88, reflecting the company's increased investment in R&D[56]. - The company has made significant progress in its R&D projects, with several key generic drugs either approved or in various stages of registration[48]. - Anglikang is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and safety[131]. - The company plans to launch three new products in the next quarter, targeting a market share increase of 10% in the respective segments[131]. Market Strategy and Expansion - The company is actively pursuing market expansion strategies and potential mergers and acquisitions to strengthen its market position[5]. - The pharmaceutical industry is expected to grow due to increasing demand driven by an aging population and high-end medical needs, despite regulatory pressures[34]. - The company is exploring market expansion opportunities in Southeast Asia, with a projected revenue increase of 20% from this region by the end of 2023[131]. - The company has initiated discussions for potential mergers and acquisitions to strengthen its market position, focusing on companies with complementary product lines[131]. - The company plans to expand its market presence by entering three new provinces in China by the end of 2022, aiming for a 20% increase in market share[133]. Risk Management - The company emphasizes the importance of risk factors including regulatory changes, rising production costs, and the impact of the ongoing pandemic on operations[5]. - The company has outlined potential risks related to talent retention and the loss of core technical personnel, which could impact future growth[5]. - The company faces ongoing risks of rising production costs and drug price reductions due to national policies, which may compress profit margins while providing opportunities for sales expansion[89]. - The company is monitoring the ongoing pandemic situation, which could adversely affect operations if outbreaks occur[95]. - The company is at risk of talent shortages and core technical personnel turnover, which could impact operational efficiency; it plans to enhance talent recruitment and internal training[93]. Environmental and Social Responsibility - The company has highlighted the importance of environmental policies and safety production measures in its operational strategy[5]. - The company has established wastewater treatment facilities with a capacity of 1000t/d at its headquarters and Jiangsu Yuexin, and 72t/d at Haixi Pharmaceutical, all operating normally[107]. - The company’s wastewater discharge meets the standards set by relevant environmental regulations, with ammonia nitrogen and total phosphorus controlled according to specific limits[108]. - The company actively participates in social welfare activities, donating 1 million to the Shenzhou Charity Association after the reporting period[121]. - The company emphasizes social responsibility, focusing on economic benefits while protecting stakeholders' rights, particularly employees and customers[115]. Corporate Governance - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management team[4]. - The company has a comprehensive governance structure in place to oversee its operations and ensure compliance with regulatory requirements[4]. - The company has established a comprehensive corporate governance structure to protect shareholder and creditor rights, ensuring transparency and fairness in information disclosure[116]. - The company prioritizes employee welfare, providing a supportive work environment and adhering to labor laws to protect employee rights[118]. Shareholder Commitments - The company has committed to not transferring or entrusting the management of its shares for 36 months following the listing of its stock[124]. - The company will notify the market in writing about any intention to reduce its holdings of shares, with a notice period of 3 trading days[124]. - The company has committed to strict compliance with regulations regarding shareholder reductions and will notify the company of any intended share reductions[126]. - The company has not reported any violations of these commitments as of the current date[126]. Financial Management - The company reported a government subsidy income of ¥3,717,386.51 during the reporting period, contributing positively to its financial performance[30]. - The company reported a significant decrease of 82.99% in notes receivable, down to ¥5,380,148.21, due to the maturity of accepted bills[63]. - The company has established a joint venture named Jianrui Pharmaceutical with Hunan Kairui Biological, which was registered in June 2022[144]. - The company has cumulatively obtained 23.48% of Keri Pharmaceutical through agreements and block trades as of the report signing date[159].

1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 浙江昂利康制药股份有限公司 2022 年第一季度报告全文 证券代码：002940 证券简称：昂利康 公告编号：2022-049 浙江昂利康制药股份有限公司 2022 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 重要内容提示: 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业收入（元） | 338,209,274.21 | 318,879,719.41 | | 6.06% | | 归属于上市公司股东的净利润（元） | 39,086,498.56 ...

Financial Performance - The company's operating revenue for 2021 was ¥1,380,377,636.93, representing a 7.04% increase compared to ¥1,289,647,101.26 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥119,844,202.86, a decrease of 26.80% from ¥163,719,116.52 in 2020[18]. - The net profit after deducting non-recurring gains and losses was ¥107,857,508.30, down 19.51% from ¥134,000,807.56 in 2020[18]. - The company's total assets at the end of 2021 were ¥2,083,578,310.62, an increase of 7.36% from ¥1,940,754,044.72 at the end of 2020[18]. - The basic earnings per share for 2021 was ¥1.27, a decline of 29.83% compared to ¥1.81 in 2020[18]. - The weighted average return on net assets decreased to 9.13% in 2021 from 16.11% in 2020, a drop of 6.98 percentage points[18]. - The net cash flow from operating activities for 2021 was ¥197,652,364.35, a slight decrease of 0.48% from ¥198,612,986.30 in 2020[18]. - The company reported a total of ¥11,986,694.56 in non-recurring gains for 2021, down from ¥29,718,308.96 in 2020[24]. Market Expansion and Product Development - The company is actively involved in new product development and has faced challenges with the consistency evaluation of major products[4]. - The company has expanded its market presence by acquiring a controlling stake in Haixi United Pharmaceutical Co., Ltd. in August 2021[12]. - The company is focusing on expanding its product line with new drugs, although future production and sales remain uncertain for many of these products[64][65]. - The company completed the registration of three new products, including compound α-keto acid tablets and sevoflurane raw materials[41]. - The company is actively expanding into new markets, including pet pharmaceuticals and medical aesthetics, through strategic partnerships and joint ventures[43]. Research and Development - The company is focused on enhancing its R&D capabilities to innovate and develop new drugs, particularly in the field of generic drugs[4]. - R&D investment has been increased to enhance project progress and attract high-end talent, focusing on differentiated competitive products in the pharmaceutical sector[41]. - The company has several new drug projects in progress, including the approval of Ticagrelor tablets and the completion of bioequivalence studies for various products[64][65]. - The number of R&D personnel increased by 22.89% to 102 in 2021 from 83 in 2020[66]. - The company plans to increase its R&D investment to enhance its core competitiveness and accelerate the development of new products, including the "HC008" project and the expansion of alpha-keto acid raw material production[108]. Risk Management - The company acknowledges various risks including rising production costs, regulatory changes, and the impact of the ongoing pandemic on operations[4]. - The company has highlighted the need for risk awareness among investors regarding potential unlisted risks[4]. - The company acknowledges the risks associated with new product development, including potential delays and failures, and plans to implement rigorous project management to mitigate these risks[117]. - The company is prepared to address the ongoing impacts of the pandemic on its operations, ensuring that production and business activities are organized effectively[119]. - The company is actively monitoring industry regulatory changes and will adapt its internal management to comply with new standards, aiming to maintain operational stability[109]. Governance and Compliance - The company emphasizes the protection of minority shareholders' rights and has conducted shareholder meetings in compliance with legal requirements, ensuring transparency and fairness[128]. - The board of directors operates with a clear division of responsibilities and has established four specialized committees to provide professional opinions for decision-making[129]. - The company adheres to strict information disclosure practices, complying with relevant laws and regulations to maintain transparency[130]. - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent communication[191]. - The company has identified no violations of national regulations or the China Securities Regulatory Commission's requirements during its governance self-inspection[177]. Environmental and Social Responsibility - The company has established wastewater treatment facilities with a design capacity of 1,000 tons per day at its headquarters and Jiangsu Yuexin, and 72 tons per day at Haixi Pharmaceutical, all operating normally[182]. - The company has implemented a robust environmental management system that meets pollution control requirements and ensures stable compliance with discharge standards[182]. - The company has achieved ISO14001 certification for its environmental management system, reflecting its commitment to environmental protection[194]. - The company has actively participated in social welfare activities, including donations of epidemic prevention materials and support for underprivileged families[195]. - The company has implemented a comprehensive review of its governance structure, financial operations, and compliance with regulatory requirements, leading to identified areas for improvement[177]. Shareholder and Financial Policies - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares to all shareholders, based on a total of 93,886,819 shares[4]. - The company maintained a transparent and compliant cash dividend policy, ensuring the protection of minority shareholders' rights[169]. - The total cash dividend, including other methods, reached RMB 91,505,097.05 for the reporting period[169]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of stock listing, with a lock-up period extending for an additional 6 months if certain conditions are met[198]. - The company must notify the stock exchange of any intended share reductions 3 trading days in advance[200].

浙江昂利康制药股份有限公司 2021 年第三季度报告 证券代码：002940 证券简称：昂利康 公告编号：2021-077 浙江昂利康制药股份有限公司 2021 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在 虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中 财务信息的真实、准确、完整。 3.第三季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 本报告期比上年同期增减 | 年初至报告期末 | 年初至报告期末比上年 | | --- | --- | --- | --- | --- | | | | | | 同期增减 | | 营业收入（元） | 353,156,522.32 | 13.80% | 986,885,462.15 | 7.47% ...

Financial Performance - The company reported a revenue of RMB 500 million for the first half of 2021, representing a year-on-year increase of 15%[15]. - The net profit attributable to shareholders was RMB 100 million, up 20% compared to the same period last year[15]. - The company's operating revenue for the first half of 2021 was ¥633,728,939.83, an increase of 4.24% compared to ¥607,928,301.13 in the same period last year[20]. - Net profit attributable to shareholders decreased by 22.91% to ¥65,580,207.38 from ¥85,071,573.20 year-on-year[20]. - The company achieved total revenue of CNY 63,372.89 million for the first half of 2021, representing a year-on-year growth of 4.24%[33]. - The net profit attributable to shareholders was CNY 6,558.02 million, a decrease of 22.91% compared to the same period last year, primarily due to a significant decline in government subsidies received[33]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion CNY for the first half of 2021, representing a 25% year-over-year growth[111]. - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 25%[111]. Research and Development - The company plans to invest RMB 50 million in R&D for new drug development in the next fiscal year[15]. - The company is focusing on the development of generic drugs, with 5 new products expected to be launched in the next 12 months[15]. - The company has made progress in the development of key generic drug projects, including the completion of registration for Ticagrelor tablets and the submission of applications for other products[35]. - The company is investing 100 million CNY in R&D for new technologies aimed at enhancing product efficacy[111]. - The company continues to focus on R&D and innovation, aiming to develop high-value generic drugs and maintain a robust product pipeline[38]. Market Expansion - User data indicates a 30% increase in the number of active customers, reaching 1 million by the end of June 2021[15]. - The company has expanded its market presence by entering two new provinces, aiming for a 10% market share in these regions by the end of 2022[15]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[107]. - Market expansion plans include entering three new provinces in China, targeting a 15% market share by 2023[111]. Strategic Initiatives - The company is exploring strategic partnerships for potential mergers and acquisitions to enhance its product portfolio[15]. - A strategic acquisition of a smaller biotech firm was announced, expected to enhance the company's R&D capabilities and add 150 million CNY in annual revenue[107]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 500 million CNY allocated for potential deals[111]. Financial Management - The company has no plans to distribute cash dividends or issue bonus shares for the current fiscal year[5]. - The company has committed to maintaining a dividend payout ratio of 30% of net profits for the next three years[107]. - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent communication[83]. - The company has committed to ensuring effective implementation of measures to compensate for immediate returns dilution following its public offering[112]. Environmental and Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[74]. - The company has strengthened its quality management system and implemented a comprehensive environmental, health, and safety (EHS) management system to ensure compliance and safety in production[37]. - The company ensures that all emissions from its production processes comply with relevant environmental standards, including strict limits on VOCs and other pollutants[76]. - The company has implemented a comprehensive monitoring system for wastewater, ensuring that all treated wastewater meets discharge standards before entering municipal systems[75]. Risks and Challenges - The management highlighted potential risks including regulatory changes and rising production costs, which could impact future performance[5]. - The company faces risks from rising production costs due to stricter national safety and environmental policies, which could impact profitability[60]. - The company is at risk of not passing the consistency evaluation for its generic drugs, which could affect market access and future operations[64]. Shareholder and Governance - The company has appointed new directors and a financial director as part of its board restructuring on January 5, 2021[69]. - The company has established a commitment to avoid engaging in any business that competes with its main operations[99]. - The company has a strategy to maintain transparency and compliance with the China Securities Regulatory Commission[94]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of stock listing[92].

Revenue and Profit - The company's revenue for Q1 2021 was CNY 318,879,719.41, representing a 4.28% increase compared to CNY 305,801,306.93 in the same period last year[7] - Net profit attributable to shareholders decreased by 21.56% to CNY 32,782,577.42 from CNY 41,793,775.21 year-on-year[7] - The net profit after deducting non-recurring gains and losses increased by 11.03% to CNY 31,269,592.62 compared to CNY 28,162,927.11 in the previous year[7] - Net profit for Q1 2021 was CNY 36,576,577.16, a decrease from CNY 44,118,468.41 in the same period last year, representing a decline of approximately 17%[43] - Total comprehensive income for the first quarter was CNY 27,436,753.47, compared to CNY 41,876,969.19 in the previous period, indicating a decrease of approximately 34.5%[48] Cash Flow - The net cash flow from operating activities was CNY 52,662,779.65, down 48.91% from CNY 103,085,670.64 in the same period last year[7] - Cash inflow from operating activities totaled CNY 396,086,372.02, a decrease from CNY 418,141,711.73 in the previous year[51] - Cash outflow from operating activities increased to CNY 343,423,592.37, compared to CNY 315,056,041.09 in the previous period, reflecting a rise of approximately 9.0%[51] - Investment activities resulted in a net cash outflow of CNY 42,650,301.10, a significant decrease from a net inflow of CNY 125,806,840.90 in the previous year[51] - The company reported a cash flow from financing activities net outflow of CNY 27,023,620.47, compared to a net inflow of CNY 9,889,031.66 in the previous year[52] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,881,859,623.93, a decrease of 3.03% from CNY 1,940,754,044.72 at the end of the previous year[7] - Current assets totaled CNY 1,316,295,205.04, down from CNY 1,393,396,544.53, indicating a decrease of about 5.55%[33] - Total liabilities decreased to CNY 476,082,970.53 from CNY 562,784,336.85, a decline of around 15.38%[35] - The total liabilities increased to CNY 380,923,351.54 from CNY 378,385,218.39 year-over-year[42] - The company's equity increased to CNY 1,405,776,653.40 from CNY 1,377,969,707.87, an increase of about 2.84%[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,322[10] - The company repurchased 514,900 shares, accounting for 0.54% of total equity, with a total transaction amount of ¥16,976,813[18] - The company plans to use between ¥50 million and ¥100 million for share repurchase, with a maximum price of ¥55.00 per share[17] Operating Costs and Expenses - Operating costs rose by 124.87% to ¥109,763,926.03 primarily due to increased raw material revenue[16] - Research and development expenses for Q1 2021 were CNY 11,344,978.86, slightly up from CNY 10,435,352.69 year-over-year[42] - The company reported a decrease in sales expenses to CNY 144,055,029.38 from CNY 195,476,379.49 in the previous year[42] Non-Recurring Gains and Losses - The company reported non-recurring gains of CNY 1,512,984.80, primarily from government subsidies and other income[8] - The company reported a significant decrease in other income by 88.14% to ¥1,787,010.20 due to reduced government grants[16] - Investment income decreased by 840.62% to -¥3,273,488.22 due to increased losses from joint ventures[16] Other Financial Metrics - Basic and diluted earnings per share decreased by 26.09% to CNY 0.34 from CNY 0.46 year-on-year[7] - The weighted average return on equity was 2.45%, down from 4.24% in the previous year, a decrease of 1.79%[7] - The company has no violations regarding external guarantees during the reporting period[26] - The company did not adjust the beginning balance of the balance sheet for the new leasing standards, indicating no significant impact on financial results[57]

Financial Performance - The company's operating revenue for 2020 was ¥1,289,647,101.26, a decrease of 7.63% compared to ¥1,396,193,906.33 in 2019[16]. - The net profit attributable to shareholders for 2020 was ¥163,719,116.52, an increase of 45.83% from ¥112,269,989.60 in 2019[16]. - The net profit after deducting non-recurring gains and losses was ¥134,000,807.56, up 28.89% from ¥103,964,289.05 in 2019[16]. - The company's total assets at the end of 2020 were ¥1,940,754,044.72, representing a 40.13% increase from ¥1,384,985,439.21 at the end of 2019[16]. - The net assets attributable to shareholders increased by 36.65% to ¥1,318,879,304.06 at the end of 2020 from ¥965,125,415.82 at the end of 2019[16]. - The basic earnings per share for 2020 were ¥1.81, a 44.80% increase from ¥1.25 in 2019[16]. - The weighted average return on equity for 2020 was 16.11%, up from 12.06% in 2019[16]. - The company reported a net cash flow from operating activities of ¥198,612,986.30, a decrease of 6.97% from ¥213,493,104.11 in 2019[16]. - In 2020, the company achieved total operating revenue of CNY 1,289,647,101.26, a decrease of 7.63% year-on-year; net profit attributable to shareholders was CNY 163,719,116.52, an increase of 45.83% year-on-year[35]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 5 RMB per 10 shares to all shareholders, based on a total of 95,431,919 shares[4]. - In 2020, the company distributed cash dividends of RMB 10.00 per 10 shares, totaling RMB 90 million, based on a total share capital of 90 million shares as of December 31, 2019[121]. - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares, totaling RMB 47,715,959.50 for the year 2020[123]. - The cash dividend for 2020 represents 29.15% of the net profit attributable to ordinary shareholders, which is RMB 163,719,116.52[125]. - The total distributable profit for 2020 is RMB 359,474,523.94, with cash dividends constituting 100% of the profit distribution[126]. - The cash dividend payout ratio has decreased significantly from 80.16% in 2019 to 29.15% in 2020[125]. Research and Development - The company is focused on the research and development of new drugs, particularly innovative and generic drugs, to meet market demands[4]. - The company has been recognized as a high-tech enterprise and has established a provincial-level research and development center, enhancing its research capabilities[38]. - The company's R&D expenses for 2020 amounted to ¥43,877,077.63, reflecting a 17.48% increase compared to 2019[65]. - The R&D investment accounted for 3.40% of total revenue, up from 2.67% in 2019, indicating a significant increase in focus on research and development[69]. - The company is engaged in multiple collaborative R&D projects, including the development of Ticagrelor tablets and other generic drugs[66]. - R&D personnel increased to 83, up by 5.06% from 79 in the previous year, maintaining a stable proportion of 9.12% of total staff[68]. Market Position and Strategy - The company aims to enhance its market position through strategic expansions and potential mergers and acquisitions in the pharmaceutical sector[4]. - The company is actively monitoring the impact of centralized drug procurement policies on its product pricing and market competitiveness[4]. - The company is focused on maintaining compliance with national drug approval standards and enhancing the quality of its pharmaceutical offerings[4]. - The company has established subsidiaries to strengthen its operational capabilities and market reach, including AngLiKang Pharmaceutical Technology and AngLiKang Capsule[9]. - The company has completed the consistency evaluation for cefaclor sustained-release tablets and has submitted registration for two specifications of amlodipine besylate tablets[43]. Industry Trends and Challenges - The pharmaceutical manufacturing industry achieved revenue of CNY 24,857.3 billion in 2020, representing a year-on-year growth of 4.5%, surpassing the national average growth rate of 3.7% for large-scale industrial enterprises[29]. - The total profit for the pharmaceutical manufacturing industry reached CNY 3,506.7 billion in 2020, with a year-on-year increase of 12.8%, also exceeding the national average growth rate of 8.7% for large-scale industrial enterprises[29]. - The aging population in China is accelerating, with the proportion of individuals aged 65 and above increasing from 10.5% in 2015 to 12.6% in 2019, indicating a growing demand for healthcare services[28]. - The average price reduction for drugs in the fourth batch of national centralized procurement was 52%, with the highest reduction reaching 96.82%, reflecting significant cost-saving measures in the industry[30]. - The success rate of the 2020 medical insurance drug directory negotiations was 73.46%, with an average price reduction of 50.64% for the negotiated drugs, indicating a trend towards more affordable medications[31]. - The traditional profit model for pharmaceuticals is being challenged due to the implementation of centralized drug procurement and consistency evaluations, leading to significant price reductions that could impact profitability[116]. Operational Risks - The company emphasizes the importance of risk awareness regarding industry regulations, production cost increases, and new product development challenges[4]. - The company faces risks from industry regulations and policy changes that could impact its operations and profitability[108]. - Rising production costs due to stricter environmental regulations and increased raw material prices pose a significant risk[109]. - New drug development is a lengthy process with potential risks including technical difficulties, policy changes, and cost overruns, which may impact the company's growth[115]. - The company primarily focuses on generic drugs, and there is a risk of failing the consistency evaluation for its formulations, which could adversely affect future business operations[113]. Corporate Governance and Compliance - The company is committed to ensuring the accuracy and completeness of its financial reports, with key management personnel affirming the integrity of the annual report[3]. - The company has established a comprehensive internal control system to protect the rights of shareholders and ensure fair treatment[180]. - The company emphasizes employee rights protection, implementing a comprehensive labor contract system and a detailed human resource management policy[182]. - The company has committed to not transferring or repurchasing shares held by major shareholders for 36 months post-IPO[129]. - The company will ensure timely communication with investors regarding compensation and will establish an investor compensation fund to address direct economic losses[141]. Environmental Responsibility - The company has achieved ISO14001 certification, demonstrating its commitment to environmental protection and sustainable practices[184]. - The company has established wastewater treatment facilities with a design capacity of 1000 tons per day at both its headquarters and Jiangsu Yuexin[191]. - The company’s wastewater treatment facilities operated normally during the reporting period, ensuring compliance with relevant discharge standards[191]. - The company completed the renewal of its national pollutant discharge permit in December 2020[196]. - The company’s emissions of COD were reported at 15.11 tons, with no exceedance of discharge standards[189]. - The company has implemented a comprehensive environmental emergency response plan, which was revised and approved by experts in 2020[197]. Social Responsibility - The company has actively participated in social welfare activities, including donations of medicines and support for underprivileged families[185]. - The company invested a total of 22.92 million yuan in various poverty alleviation initiatives[188]. - The company donated pharmaceuticals in response to the call from the Shengzhou Charity Association, contributing to poverty alleviation efforts[187].

Financial Performance - Net profit attributable to shareholders rose by 55.40% to CNY 39,156,146.83 for the reporting period[7] - The company reported a net profit of CNY 124,227,720.03 for the year-to-date, a 37.41% increase compared to the same period last year[7] - Net profit for the quarter was CNY 43,712,488.51, up from CNY 30,237,455.39, representing a growth of approximately 44.6%[48] - The total comprehensive income for the period was CNY 43,712,488.51, compared to CNY 30,237,455.39 in the previous period, indicating overall growth[49] - Net profit for the third quarter was ¥36,674,809.75, up 8.23% from ¥33,805,184.12 year-over-year[56] - The total comprehensive income for the period was ¥136,218,844.80, an increase of 37.06% from ¥99,340,202.91 year-over-year[57] Revenue and Income - Operating income decreased by 2.73% to CNY 310,319,905.54 compared to the same period last year[7] - Total operating revenue for the third quarter was CNY 310,319,905.54, a decrease from CNY 319,028,266.62 in the previous period[46] - Total operating revenue for the third quarter was ¥918,248,206.67, a decrease of 13.98% compared to ¥1,067,030,111.04 in the same period last year[54] - The company's operating revenue for Q3 2020 was ¥538,548,631.73, a decrease of 7.3% compared to ¥580,982,031.05 in the same period last year[59] Cash Flow - Net cash flow from operating activities increased by 95.88% to CNY 78,633,589.25[7] - Cash generated from operating activities increased by 31.44% to ¥180,596,804.44, mainly due to reduced payments for raw materials[18] - Operating cash flow for the period was CNY 173,425,940.80, an increase of 17.5% compared to the previous period's CNY 147,576,171.86[66] - The net cash flow from operating activities was ¥180,596,804.44, up from ¥137,396,281.17 in the previous year, indicating improved cash generation[64] Assets and Liabilities - Total assets increased by 6.22% to CNY 1,471,154,118.97 compared to the end of the previous year[7] - Total liabilities reached CNY 408,877,694.74, up from CNY 368,512,617.20, which is an increase of about 10.9%[40] - The company's equity attributable to shareholders increased to CNY 998,937,893.27 from CNY 965,125,415.82, showing a growth of approximately 3.5%[41] - Total liabilities increased to CNY 323,533,055.42 from CNY 214,531,959.18, indicating potential leverage for growth[47] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,022[11] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 37.78% of the shares[11] Research and Development - R&D expenses increased by 66.64% to ¥28,790,171.53, reflecting higher investment in research and development[17] - Research and development expenses rose to CNY 10,564,768.70 from CNY 6,696,827.25, highlighting a commitment to innovation[47] - Research and development expenses increased to ¥24,751,839.50 from ¥15,111,410.73, reflecting a focus on innovation and new product development[59] Government Support - The company received government subsidies totaling ¥35,857,867 during the reporting period[19] - The company received government subsidies that increased compared to the previous year, contributing positively to the overall performance[28] Strategic Initiatives - A strategic cooperation agreement was signed with Chuaning Biological to enhance collaboration in the cephalosporin raw material drug supply chain[20] - The company plans to continue expanding its market presence and investing in new product development[49] - The company plans to continue its market expansion and product development strategies to sustain growth in the upcoming quarters[61] Investment Activities - Investment activities generated cash of ¥64,174,832.93, a significant change due to the redemption of structured deposits[18] - The company has ongoing construction projects with capitalized costs of CNY 92,876,045.22, significantly up from CNY 42,255,968.56, representing an increase of approximately 119.5%[39] Financial Management - The total amount of entrusted financial management was RMB 150 million, with no overdue amounts reported[30] - The company has completed 100.66% of the planned investment for working capital, totaling RMB 146.75 million[26]